BG

Bellevue Group Portfolio holdings

AUM $4.54B
1-Year Est. Return 22.5%
This Quarter Est. Return
1 Year Est. Return
+22.5%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$4.46B
AUM Growth
-$732M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
170
New
Increased
Reduced
Closed

Top Buys

1
+$50.6M
2
+$18.9M
3
+$17.3M
4
BEAM icon
Beam Therapeutics
BEAM
+$17.1M
5
BAX icon
Baxter International
BAX
+$15.6M

Top Sells

1
+$204M
2
+$45.8M
3
+$36.1M
4
VRNA
Verona Pharma
VRNA
+$32.2M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$28.2M

Sector Composition

1 Healthcare 99.87%
2 Technology 0.01%
3 Communication Services 0.01%
4 Consumer Discretionary 0%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
151
Autolus Therapeutics
AUTL
$431M
– –
-41,500
BPMC
152
DELISTED
Blueprint Medicines
BPMC
– –
-3,200
CRL icon
153
Charles River Laboratories
CRL
$8.79B
– –
-50,327
DNLI icon
154
Denali Therapeutics
DNLI
$2.44B
– –
-15,700
FATE icon
155
Fate Therapeutics
FATE
$170M
– –
-4,839,779
GOOG icon
156
Alphabet (Google) Class C
GOOG
$3.07T
– –
-6,000
KNSA icon
157
Kiniksa Pharmaceuticals
KNSA
$2.86B
– –
-8,100
KURA icon
158
Kura Oncology
KURA
$854M
– –
-13,600
NRIX icon
159
Nurix Therapeutics
NRIX
$757M
– –
-8,000
OMCL icon
160
Omnicell
OMCL
$1.37B
– –
-94,740
RARE icon
161
Ultragenyx Pharmaceutical
RARE
$3.14B
– –
-4,000
ROIV icon
162
Roivant Sciences
ROIV
$11.8B
– –
-24,000
SAGE
163
DELISTED
Sage Therapeutics
SAGE
– –
-4,460,693
TERN icon
164
Terns Pharmaceuticals
TERN
$736M
– –
-1,061,753
TNDM icon
165
Tandem Diabetes Care
TNDM
$999M
– –
-782,456
VCYT icon
166
Veracyte
VCYT
$2.82B
– –
-3,600
VKTX icon
167
Viking Therapeutics
VKTX
$3.77B
– –
-12,939
XENE icon
168
Xenon Pharmaceuticals
XENE
$3.21B
– –
-8,200
ACCD
169
DELISTED
Accolade Inc
ACCD
– –
-615,509
ITCI
170
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-2,440,240
3 4 5 6
7